See Inside May 2006

Blockbuster Dreams

New understanding of the biology behind a successful cancer therapy may lead to a drug that can treat an array of solid tumors

From the time it was approved in 1998, Genentech's Herceptin--a drug in the vanguard of the first generation of so-called targeted therapeutics--has achieved an impressive track record for a subset of breast cancer patients. Some patients who take it live longer and the size of their tumors is kept under better control than if they had received standard chemotherapy alone.

To develop Herceptin, researchers at Genentech drew on investigations into the molecular workings of a cancer cell. Some breast cancer cells stud their exterior with a surfeit of receptors that join in pairs to trigger a cascade of signals that cause the cells to replicate uncontrollably, develop resistance to chemotherapy and encourage the growth of blood vessels that promote the spread of tumor cells.

This is only a preview. Get the rest of this article now!

Select an option below:

Customer Sign In

*You must have purchased this issue or have a qualifying subscription to access this content

It has been identified that the institution you are trying to access this article from has institutional site license access to Scientific American on
Click here to access this article in its entirety through site license access.

Rights & Permissions
Share this Article:


You must sign in or register as a member to submit a comment.
Scientific American Holiday Sale

Scientific American Mind Digital

Get 6 bi-monthly digital issues
+ 1yr of archive access for just $9.99

Hurry this offer ends soon! >


Email this Article


Next Article